



## Praxis Precision Medicines to Present at Upcoming December Investor Conferences

December 3, 2024 at 8:00 AM EST

BOSTON, Dec. 03, 2024 (GLOBE NEWSWIRE) -- [Praxis Precision Medicines](#), Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance, today announced that it will be participating in two upcoming investor conferences in December 2024.

- Praxis management will be participating in a fireside chat at the **Piper Sandler 36<sup>th</sup> Annual Healthcare Conference**, taking place in New York, NY at the Lotte New York Palace Hotel on December 4, 2024 at 2:00pm ET. A live webcast of the event will be available through this [link](#).
- Praxis management will also be participating in a panel titled "Elevator Pitches from Rare Disease Companies with Key Near-term, Potentially Stock-moving Catalysts" at the **Oppenheimer Movers in Rare Disease Summit**, taking place in New York, NY at the Westin Grand Central Hotel on December 12, 2024 at 2:00pm ET.

The Company will be available for one-on-one meetings during these conferences. Interested investors should contact their respective Piper Sandler and/or Oppenheimer representatives to request meetings.

The Piper Sandler live webcast will also be available through the "Upcoming & Recent Events" page of the Investors + Media section of the company's website at [www.praxismedicines.com](http://www.praxismedicines.com). Following the event, a replay will be posted, when available, to Praxis' website on the "[Events and Presentations](#)" page under the investor section of the website for 90 days.

### About Praxis

Praxis Precision Medicines is a clinical-stage biopharmaceutical company translating insights from genetic epilepsies into the development of therapies for CNS disorders characterized by neuronal excitation-inhibition imbalance. Praxis is applying genetic insights to the discovery and development of therapies for rare and more prevalent neurological disorders through our proprietary small molecule platform, Cerebrum™, and antisense oligonucleotide (ASO) platform, Solidus™, using our understanding of shared biological targets and circuits in the brain. Praxis has established a diversified, multimodal CNS portfolio including multiple programs across movement disorders and epilepsy, with four clinical-stage product candidates. For more information, please visit [www.praxismedicines.com](http://www.praxismedicines.com) and follow us on [Facebook](#), [LinkedIn](#) and [Twitter/X](#).

Investor Contact: Praxis Precision Medicines [investors@praxismedicines.com](mailto:investors@praxismedicines.com) 857-702-9452 Media Contact: Dan Ferry Life Science Advisors [Daniel@lifesciadvisors.com](mailto:Daniel@lifesciadvisors.com) 617-430-7576